Sponsor or institution

Clinical trials and research at AbbVie

• 111Clinical trials
• 4New in 30 days
• 49Countries

Newest trials

All recruiting trials (111)

• How trosunilimab moves through the body after IV and SC doses in healthy adults

  This study tests how trosunilimab behaves in the body and how the immune system reacts to it after intravenous and subcutaneous doses in healthy adults.

  Recruiting Phase 1 AbbVie · Grayslake, Illinois · NCT07925983

• Real-world use of mirvetuximab soravtansine in FRα-positive platinum-resistant ovarian, fallopian tube, and peritoneal cancer

  This study tests how mirvetuximab soravtansine works in real-world adults with FRα-positive platinum-resistant ovarian, fallopian tube, or peritoneal cancer.

  Recruiting AbbVie · Vienna · NCT07896421

• NOA HYDRATION facial gel: see if it can improve skin smoothness

  This study tests whether NOA HYDRATION injectable gel can improve facial skin quality and smoothness in Chinese adults.

  Recruiting at 4 sites Phase 3 AbbVie · Beijing, Beijing Municipality and 3 other locations · NCT07880756

• Combination of two botulinum toxins for upper facial lines in adults

  This study tests whether a single treatment that combines trenibotulinumtoxinE with onabotulinumtoxinA can improve moderate to severe upper facial lines in adults.

  Recruiting at 21 sites Phase 2 AbbVie · Birmingham, Alabama and 20 other locations · NCT07871513

• ABBV-7828 safety and food effect study in healthy adults

  This study tests ABBV-7828 versus placebo in healthy adults to see how safe it is, how it behaves in the body, and how food changes its effects.

  Recruiting Phase 1 AbbVie · Grayslake, Illinois · NCT07856706

• Safety and drug level study of multiple doses of upadacitinib, tofacitinib, and baricitinib in healthy adults

  This early-phase study tests how different doses of upadacitinib, tofacitinib, and baricitinib behave in healthy adults to understand safety and how the drugs act in the body.

  Recruiting Phase 1 AbbVie · Grayslake, Illinois · NCT07843693

• ABBV-253 in adults with advanced solid tumors

  This study tests ABBV-253 to see if it is safe, how it affects the cancer, and how the drug moves in the body for adults with advanced solid tumors.

  Recruiting at 3 sites Phase 1 AbbVie · Grand Rapids, Michigan and 2 other locations · NCT07807956

• Jawline and neck treatment satisfaction in adults

  This study tests whether a combination of injectables for the jawline and neck increases participant satisfaction in adults with concerns about jawline and neck appearance.

  Recruiting at 2 sites Phase 4 AbbVie · Vancouver, British Columbia and 1 other locations · NCT07794891

• Safety and effectiveness of NOA LIFT vs VOLIFT for correcting nasolabial folds in adults

  This study tests whether NOA LIFT works as well as JUVÉDERM VOLIFT with lidocaine for correcting moderate to severe nasolabial folds in adults.

  Recruiting at 6 sites Phase 3 AbbVie · Beijing, Beijing Municipality and 5 other locations · NCT07794878

• Upadacitinib for Severe Alopecia Areata in Children

  This study tests whether upadacitinib can safely help children with severe alopecia areata grow back hair, compared with placebo.

  Recruiting at 14 sites Phase 3 AbbVie · Los Angeles, California and 13 other locations · NCT07772492

• Telisotuzumab Adizutecan with Gemcitabine and Nab-Paclitaxel in Pancreatobiliary Cancers

  This study tests whether adding telisotuzumab adizutecan to standard chemotherapy can help adults with pancreatobiliary cancers see a benefit.

  Recruiting at 7 sites Phase 2 AbbVie · Hattiesburg, Mississippi and 6 other locations · NCT07769502

• ABBV-1480 plus chemotherapy vs pembrolizumab plus chemotherapy as first-line treatment for locally advanced or metastatic non-small cell lung cancer

  This study tests whether ABBV-1480 with platinum-based chemotherapy can work better than pembrolizumab with chemotherapy for adults with certain stages of non-small cell lung cancer.

  Recruiting at 2 sites Phase 3 AbbVie · Fort Wayne, Indiana and 1 other locations · NCT07756645

• ABBV-295 for weight management in adults with obesity or overweight

  This study tests whether ABBV-295, given as injections, helps people with obesity or overweight and related health conditions lose weight compared to placebo.

  Recruiting at 64 sites Phase 2 AbbVie · Pelham, Alabama and 63 other locations · NCT07752979

• Telisotuzumab Adizutecan with Pembrolizumab as first-line treatment for recurrent or metastatic head and neck cancer

  This study tests a combination treatment to see if it helps people with newly diagnosed recurrent or metastatic head and neck squamous cell carcinoma who express the c-Met protein.

  Recruiting at 5 sites Phase 2 AbbVie · Duarte, California and 4 other locations · NCT07744126

• ABBV-859: testing single-dose safety and how the medicine moves through the body in healthy adults

  This study tests a single escalating dose of ABBV-859 in healthy adults to see how it behaves in the body and how well it is tolerated.

  Recruiting at 2 sites Phase 1 AbbVie · Anaheim, California and 1 other locations · NCT07736638

• Advanced therapies for moderately to severely active Crohn's disease or ulcerative colitis in adults

  This study tests combinations of risankizumab with either trosunilimab or ABBV-701 in adults with moderately to severely active Crohn's disease or ulcerative colitis.

  Recruiting at 66 sites Phase 2 AbbVie · Dothan, Alabama and 65 other locations · NCT07697456

• ABBV-313 safety and tolerability in healthy adults

  This study tests single and multiple doses of ABBV-313 in healthy adults to see how safe it is and how the body handles it, compared with placebo.

  Recruiting at 2 sites Phase 1 AbbVie · Anaheim, California and 1 other locations · NCT07673120

• Medication AGN-151607-DP to help upper limb tremor in adults

  This study tests whether AGN-151607-DP can safely reduce symptoms in adults with upper limb essential tremor compared with a placebo.

  Recruiting at 21 sites Phase 2 AbbVie · Carlsbad, California and 20 other locations · NCT07673107

• ABBV-519 in adults with SLE or RA: safety and how the drug moves through the body after IV and subcutaneous doses

  This early study tests how ABBV-519 behaves in the body and its safety for adults with SLE or RA after single escalating doses.

  Recruiting at 15 sites Phase 1 AbbVie · Anniston, Alabama and 14 other locations · NCT07607964

• ABBV-1758 in Alzheimer's Disease: safety and effects after injections

  This early-stage study tests ABBV-1758, given by injection or IV, to see if it’s safe and how well it works in people with Alzheimer’s disease.

  Recruiting at 13 sites Phase 1/2 AbbVie · Irvine, California and 12 other locations · NCT07599670

• Surabgene Lomparvovec in the Suprachoroidal Space for Diabetic Retinopathy

  This study tests a one-time gene therapy called surabgene lomparvovec to see if it can help adults with non-proliferative diabetic retinopathy avoid vision-threatening events.

  Recruiting at 40 sites Phase 2/3 AbbVie · Mesa, Arizona and 39 other locations · NCT07592273

• Pivekimab Sunirine with Venetoclax and Azacitidine in AML for patients who can’t have intensive chemo

  This study tests whether giving Pivekimab Sunirine together with venetoclax and azacitidine can be tolerated and may help adults with AML who aren’t eligible for intensive chemotherapy.

  Recruiting at 38 sites Phase 2/3 AbbVie · Duarte, California and 37 other locations · NCT07581002

• ABBV-1451: testing how the drug behaves and tolerates in healthy adults

  This study tests ABBV-1451 at increasing single doses to see how the body handles it, safety, and any immune responses in healthy adult volunteers.

  Recruiting Phase 1 AbbVie · Grayslake, Illinois · NCT07570147

• Prevalence of Folate Receptor Alpha in Adult Women with Ovarian Cancer Across InterCon Countries

  This study tests whether folate receptor alpha is present in tumor samples from adult women with ovarian cancer to see how common it is.

  Recruiting at 12 sites AbbVie · Buenos Aires, Buenos Aires and 11 other locations · NCT07539844

• Telisotuzumab Adizutecan with Bevacizumab vs LONSURF with Bevacizumab in refractory metastatic colorectal cancer

  This study tests whether adding telisotuzumab adizutecan to bevacizumab helps adults with refractory metastatic colorectal cancer more than the standard care of LONSURF plus bevacizumab.

  Recruiting at 88 sites Phase 3 AbbVie · Goodyear, Arizona and 87 other locations · NCT07525206

• Telisotuzumab adizutecan with FOLFOX versus standard care in first-line metastatic pancreatic cancer

  This study tests whether adding telisotuzumab adizutecan to FOLFOX helps adults with unresectable, metastatic pancreatic cancer compare to standard treatment.

  Recruiting at 22 sites Phase 2/3 AbbVie · New Haven, Connecticut and 21 other locations · NCT07490301

• How risankizumab moves through the body after IV vs SC dosing in healthy adults

  This study tests how risankizumab behaves in the body after intravenous and subcutaneous doses in healthy adult volunteers.

  Recruiting at 2 sites Phase 1 AbbVie · Anaheim, California and 1 other locations · NCT07466550

• Glecaprevir/pibrentasvir safety in people taking prescription or illicit drugs

  This will see if an 8-week course of glecaprevir/pibrentasvir is safe and works for people with hepatitis C who are taking prescription or illicit drugs.

  Recruiting at 2 sites AbbVie · Vancouver, British Columbia and 1 other locations · NCT07419347

• Intravenous ABBV-438 for relapsed/refractory multiple myeloma

  This will test IV ABBV-438 in adults with relapsed or refractory multiple myeloma to find a safe dose and see how the drug moves through the body.

  Recruiting at 14 sites Phase 1 AbbVie · Duarte, California and 13 other locations · NCT07409246

• FRα Status in High-Grade Serous Ovarian/Peritoneal Cancer

  This study tests whether tumors from adults with relapsed or newly diagnosed high-grade serous ovarian, fallopian tube, or primary peritoneal cancer show FRα positivity using a standardized staining method.

  Recruiting AbbVie · Rome, Roma · NCT07407062

• Symptom changes with subcutaneous Foslevodopa/Foscarbidopa in adults with advanced Parkinson's disease in Belgium

  This project will try subcutaneous Foslevodopa/Foscarbidopa in adults with advanced Parkinson's disease to see how their symptoms change over 18 months.

  Recruiting at 12 sites AbbVie · Bonheiden, Antwerpen and 11 other locations · NCT07382440

• ABBV-706 plus standard care for relapsed/refractory small cell lung cancer

  This study tests ABBV-706 to see if it changes disease activity and how safe it is compared with standard care in adults whose small cell lung cancer has returned or progressed.

  Recruiting at 72 sites Phase 3 AbbVie · Birmingham, Alabama and 71 other locations · NCT07365241

• Using ubrogepant during the migraine prodrome to reduce attack severity

  This project will try taking oral ubrogepant during the migraine prodrome to see if it reduces attack severity in adults who already take ubrogepant.

  Recruiting at 3 sites AbbVie · Aliso Viejo, California and 2 other locations · NCT07310290

• Pivekimab Sunirine in Children with Relapsed or Refractory AML

  This study tests how pivekimab sunirine behaves in the body and its safety in children whose AML has returned or not responded to treatment.

  Recruiting at 14 sites Phase 1 AbbVie · Palo Alto, California and 13 other locations · NCT07306832

• Safety and how the body handles ABBV-243 in healthy adults

  This test checks whether ABBV-243 is safe and how the body processes it when given as a single IV or under-the-skin dose to healthy adults, including a small group of Asian volunteers.

  Recruiting Phase 1 AbbVie · Grayslake, Illinois · NCT07306754

• Sleep changes in adults with advanced Parkinson's taking subcutaneous foslevodopa/foscarbidopa.

  This will see if subcutaneous foslevodopa/foscarbidopa improves sleep disturbances in adults with advanced Parkinson's disease who are prescribed the medication.

  Recruiting at 16 sites AbbVie · Málaga, Andalusia and 15 other locations · NCT07284342

• IV ABBV901 alone and with bevacizumab for platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer

  This will test IV ABBV901, alone and together with bevacizumab, in adults with platinum-resistant high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer to see if it is safe and helps control disease.

  Recruiting at 27 sites Phase 1 AbbVie · Duarte, California and 26 other locations · NCT07278336

• Oral icalcaprant for adults with major depressive disorder

  This trial tests whether oral icalcaprant can reduce depressive symptoms and be tolerated by adults currently experiencing a major depressive episode.

  Recruiting at 33 sites Phase 2 AbbVie · Dothan, Alabama and 32 other locations · NCT07276997

• Trying oral ABBV-711 alone and with budigalimab for advanced squamous tumors.

  This trial will test whether oral ABBV-711, alone or with the antibody budigalimab, is safe and can help adults whose advanced squamous tumors have progressed after standard treatments.

  Recruiting at 13 sites Phase 1 AbbVie · Duarte, California and 12 other locations · NCT07241039

• ABBV-142 to check side effects and changes in disease activity in adults with idiopathic pulmonary fibrosis.

  Adults with idiopathic pulmonary fibrosis will be randomly given ABBV-142 or a placebo to see if ABBV-142 is safe and changes disease activity.

  Recruiting at 57 sites Phase 2 AbbVie · Birmingham, Alabama and 56 other locations · NCT07230288

• Real-world look at Foslevodopa/Foscarbidopa for people with early advanced Parkinson’s

  This observational study will see if Foslevodopa/Foscarbidopa helps adults with Parkinson’s earlier in the advanced stage when used in routine care.

  Recruiting at 26 sites AbbVie · Boca Raton, Florida and 25 other locations · NCT07227896

• AGN-151607-DP to help close the belly wall after open midline ventral hernia repair

  This trial tests whether a single intramuscular dose of AGN-151607-DP helps safely close the belly wall in adults having open midline ventral hernia repair.

  Recruiting at 11 sites Phase 2 AbbVie · Riverside, California and 12 other locations · NCT07226791

• Oral emraclidine absorption and tolerability in healthy older adults

  This trial will test how the pill emraclidine moves through the body and how well healthy older adults tolerate it.

  Recruiting at 4 sites Phase 1 AbbVie · Cypress, California and 4 other locations · NCT07219030

• ELAPR002f injectable gel for adult atrophic acne scars

  This study will test whether ELAPR002f injectable gel can safely fill and improve atrophic acne scars in adults with moderate to severe scarring.

  Recruiting at 10 sites Phase 3 AbbVie · Glendale, Arizona and 9 other locations · NCT07207369

• Telisotuzumab adizutecan for advanced solid tumors with MET amplification (ages 12+)

  This trial will try an IV drug called telisotuzumab adizutecan in people 12 years and older whose advanced solid tumors have MET amplification to see if it can control tumor activity and what side effects occur.

  Recruiting at 38 sites Phase 2 AbbVie · Beverly Hills, California and 37 other locations · NCT07196644

• Eye injections of ABBV-6628 for geographic atrophy from age-related macular degeneration

  This trial will test whether intravitreal ABBV-6628 is safe and how the drug moves through the body in adults aged 50 and older with geographic atrophy from AMD.

  Recruiting at 5 sites Phase 1/2 AbbVie · Carmel, Indiana and 4 other locations · NCT07160179

• IV telisotuzumab adizutecan versus standard treatment for adults with advanced EGFR‑mutated non‑squamous NSCLC

  This trial tests whether IV telisotuzumab adizutecan works better than standard treatment for adults with advanced non‑squamous non‑small cell lung cancer that has EGFR exon 19 deletion or L858R mutation.

  Recruiting at 117 sites Phase 2/3 AbbVie · Springdale, Arkansas and 116 other locations · NCT07155187

• ABBV-706 plus atezolizumab versus standard first-line therapy for extensive-stage small cell lung cancer

  This trial will test whether giving ABBV-706 with atezolizumab is safer or more effective than standard first-line chemo plus atezolizumab in adults with previously untreated extensive-stage small cell lung cancer.

  Recruiting at 70 sites Phase 2 AbbVie · New Haven, Connecticut and 69 other locations · NCT07155174

• Oral emraclidine for safety, symptom change, and how the body processes it in adults with schizophrenia

  This trial will test whether oral emraclidine is safe, how the body processes it, and whether it can change symptoms in adults with schizophrenia.

  Recruiting at 7 sites Phase 2 AbbVie · Little Rock, Arkansas and 6 other locations · NCT07145918

• Global assessment of disease burden in adolescents and adults with alopecia areata, vitiligo, or hidradenitis suppurativa

  This project will see if collecting real-world information from adolescents and adults with moderate or severe alopecia areata, non-segmental vitiligo, or hidradenitis suppurativa can describe their disease burden worldwide.

  Recruiting at 116 sites AbbVie · Ciudad Autonoma de Buenos Aire, Buenos Aires and 115 other locations · NCT07136467

• Risankizumab for moderate to severe ulcerative colitis in Japanese adults: change in disease activity

  We will see if risankizumab, given as part of routine care, improves disease activity in Japanese adults with moderate to severe ulcerative colitis.

  Recruiting at 29 sites AbbVie · Nagakute, Aichi-ken and 28 other locations · NCT07136116

• Etentamig plus daratumumab versus daratumumab‑lenalidomide‑dexamethasone for newly diagnosed multiple myeloma in patients not eligible for transplant

  This trial will test whether adding the investigational drug etentamig to daratumumab helps control disease and is safe in adults newly diagnosed with multiple myeloma who cannot have a transplant.

  Recruiting at 49 sites Phase 2/3 AbbVie · Scottsdale, Arizona and 48 other locations · NCT07095452

• Second-line treatment with upadacitinib or risankizumab for adults with Crohn's disease

  This project will test how well upadacitinib or risankizumab work as second-line treatments for adults with moderate-to-severe Crohn's disease who previously used a TNF inhibitor.

  Recruiting at 25 sites AbbVie · Castellana Grotte, Bari and 24 other locations · NCT07073079

• ABBV-932 with itraconazole in bipolar disorder: how the drug moves through the body and what side effects occur

  This early-phase study tests whether ABBV-932, taken with itraconazole, is safe and how it behaves in adults with bipolar disorder.

  Recruiting Phase 1 AbbVie · Los Alamitos, California and 1 other locations · NCT07071532

• How risankizumab works in children and teens with ulcerative colitis

  This trial tests risankizumab in children and adolescents with moderate to severe ulcerative colitis to see how the medicine moves through their bodies and whether it is safe and helps their condition.

  Recruiting at 73 sites Phase 3 AbbVie · Phoenix, Arizona and 72 other locations · NCT07071519

• Mirvetuximab soravtansine combined with bevacizumab or carboplatin for FRα‑positive ovarian cancer

  This Phase 2 trial tests whether giving intravenous mirvetuximab soravtansine with bevacizumab or carboplatin is safe and can change disease activity in adults with folate receptor alpha (FRα)–positive high‑grade ovarian, fallopian tube, or primary peritoneal cancer.

  Recruiting at 85 sites Phase 2 AbbVie · La Jolla, California and 85 other locations · NCT07059845

• Oral venetoclax with injectable azacitidine for newly diagnosed AML patients who cannot have intensive chemotherapy in India

  This trial tests whether adding oral venetoclax to azacitidine injections helps adults in India with newly diagnosed acute myeloid leukemia (AML) who are not eligible for standard intensive chemotherapy.

  Recruiting at 11 sites Phase 4 AbbVie · Gurgaon, Haryana and 13 other locations · NCT07044687

• Risankizumab for improving quality of life in adults with moderate-to-severe plaque psoriasis

  See if risankizumab improves quality of life for adults with moderate-to-severe plaque psoriasis treated in routine clinical care.

  Recruiting at 82 sites AbbVie · Calgary, Alberta and 83 other locations · NCT07039110

• IMGN151 alone or with carboplatin, olaparib, or bevacizumab for adults with high-grade serous gynecologic cancers

  This trial tests whether IV IMGN151, given alone or with carboplatin, olaparib, or bevacizumab, can reduce disease activity and be safely tolerated in adults with high-grade serous ovarian, fallopian tube, or primary peritoneal cancer.

  Recruiting at 21 sites Phase 2 AbbVie · Los Angeles, California and 20 other locations · NCT07024784

• Comparing IV telisotuzumab adizutecan versus standard care for colorectal cancer patients who are ctDNA-positive with no visible disease

  This tests whether an IV drug, telisotuzumab adizutecan, or standard care can help adults with colorectal cancer who are ctDNA-positive after adjuvant therapy but have no visible disease on scans.

  Recruiting at 47 sites Phase 2 AbbVie · Huntsville, Alabama and 47 other locations · NCT07023289

• Surabgene Lomparvovec to reduce injections and preserve vision in adults with wet AMD

  This study will test whether a single subretinal dose of Surabgene Lomparvovec can reduce the need for repeated eye injections and help preserve vision in adults 50 and older with previously treated neovascular (wet) AMD compared with standard ranibizumab care.

  Recruiting at 138 sites Phase 3 AbbVie · Mesa, Arizona and 137 other locations · NCT07007065

• Telisotuzumab adizutecan plus osimertinib for first-line treatment of advanced EGFR-mutated non-squamous NSCLC

  This test adds the investigational drug telisotuzumab adizutecan to osimertinib (or to osimertinib plus chemotherapy) to see if it helps adults with newly diagnosed advanced EGFR-mutated non-squamous non-small cell lung cancer and to check side effects.

  Recruiting at 63 sites Phase 2/3 AbbVie · Chandler, Arizona and 64 other locations · NCT07005102

• Intravenous ABBV-319 for adults with SLE or Sjögren's disease

  This trial will test whether two IV doses of ABBV-319 given 21 days apart are safe, reach expected blood levels, and might help adults with SLE or Sjögren's disease.

  Recruiting at 9 sites Phase 1 AbbVie · Avon Park, Florida and 10 other locations · NCT06977724

• Targeted treatment with lutikizumab and ravagalimab for rheumatoid arthritis

  This Phase 2 trial will test whether lutikizumab, ravagalimab, or their combination reduce symptoms in people with moderately to severely active rheumatoid arthritis who have failed 1–2 prior biologic or targeted therapies.

  Recruiting at 96 sites Phase 2 AbbVie · Peoria, Arizona and 95 other locations · NCT06972446

• Foslevodopa/foscarbidopa infusion to improve quality of life for adults with advanced Parkinson disease

  This project will test whether subcutaneous foslevodopa/foscarbidopa helps quality of life for Italian adults with advanced, levodopa-responsive Parkinson disease and will also look at caregiver quality of life when a caregiver is present.

  Recruiting at 19 sites AbbVie · Troina, Enna and 18 other locations · NCT06965374

• Oral ABBV-453 alone or with daratumumab and other myeloma medicines for adults with multiple myeloma

  This trial tests whether oral ABBV-453, given alone or with daratumumab plus dexamethasone and sometimes pomalidomide, is safe and can lower disease activity in adults with relapsed or refractory multiple myeloma.

  Recruiting at 51 sites Phase 1/2 AbbVie · Los Angeles, California and 50 other locations · NCT06953960

• Observing treatment experiences with foslevodopa/foscarbidopa in advanced Parkinson's disease

  This study is looking at how patients with advanced Parkinson's disease feel while using a new treatment called foslevodopa/foscarbidopa through a pump to see how it works in real-life settings.

  Recruiting at 3 sites AbbVie · Graz, Styria and 3 other locations · NCT06937034

• Real-world foslevodopa/foscarbidopa treatment for adults with early advanced Parkinson's in Germany

  This project will test how well subcutaneous foslevodopa/foscarbidopa works for German adults with early-stage advanced Parkinson's disease when given during routine clinical care.

  Recruiting at 19 sites AbbVie · Allensbach, Baden-Wurttemberg and 18 other locations · NCT06916507

• IV etentamig plus oral iberdomide for adults with relapsed or refractory multiple myeloma

  This trial will test whether IV etentamig given with oral iberdomide is safe and changes disease activity in adults with relapsed or refractory multiple myeloma.

  Recruiting at 27 sites Phase 1 AbbVie · Beverly Hills, California and 26 other locations · NCT06896916

• Etentamig (ABBV-383) alone or with daratumumab, lenalidomide, dexamethasone, or carfilzomib for adults with multiple myeloma.

  This will test whether etentamig (ABBV-383), given by IV alone or with daratumumab, lenalidomide, dexamethasone, or carfilzomib, is safe and helps adults with multiple myeloma, including relapsed or refractory disease.

  Recruiting at 36 sites Phase 1/2 AbbVie · Duarte, California and 35 other locations · NCT06892522

• Combining carboplatin with mirvetuximab soravtansine before surgery for FRα-positive advanced serous ovarian, fallopian tube, or primary peritoneal cancer

  This will test whether giving mirvetuximab soravtansine with carboplatin before surgery helps people with newly diagnosed FRα-positive advanced-stage serous ovarian, fallopian tube, or primary peritoneal cancer.

  Recruiting at 71 sites Phase 2 AbbVie · Birmingham, Alabama and 72 other locations · NCT06890338

• Targeted therapies for treating active psoriatic arthritis in adults

  This study is testing if two different treatments for active psoriatic arthritis can help adults feel better and improve their symptoms.

  Recruiting at 35 sites Phase 2 AbbVie · Huntington Beach, California and 40 other locations · NCT06865105

• Assessing the effects of ABBV-324 on liver and lung cancers

  This study is testing a new drug called ABBV-324 to see if it can help adults with advanced liver or lung cancer feel better when taken alone or with another medication.

  Recruiting at 21 sites Phase 1 AbbVie · Duarte, California and 21 other locations · NCT06858813

• Assessing the safety and effectiveness of ABBV-932 for anxiety treatment

  This study is testing a new drug called ABBV-932 to see if it can help adults with generalized anxiety disorder who aren't feeling better with their current antidepressants.

  Recruiting at 50 sites Phase 2 AbbVie · Huntsville, Alabama and 51 other locations · NCT06846320

• Evaluating Upadacitinib for Ulcerative Colitis in Chinese Adults

  This study is testing how well upadacitinib works and how safe it is for Chinese adults with moderate to severe ulcerative colitis.

  Recruiting at 3 sites AbbVie · Guangzhou, Guangdong and 2 other locations · NCT06838845

• Assessing Epcoritamab for Adult Patients with Advanced Lymphoma

  This study is testing if a new skin injection called epcoritamab can help adults with advanced lymphoma feel better and improve their health.

  Recruiting at 73 sites AbbVie · Ciudad Autonoma de Buenos Aire, Buenos Aires and 72 other locations · NCT06830759

• Assessing the safety and effectiveness of a glaucoma gel stent implantation

  This study is testing a new gel stent for treating glaucoma to see if it works well and is safe for people over 45 who haven't had success with other treatments.

  Recruiting at 25 sites Phase 3 AbbVie · Glendale, Arizona and 28 other locations · NCT06822738

• Evaluating a new treatment for metastatic colorectal cancer

  This study is testing a new drug combined with standard chemotherapy to see if it helps adults with metastatic colorectal cancer feel better and improve their condition.

  Recruiting at 82 sites Phase 2 AbbVie · Duarte, California and 81 other locations · NCT06820463

• Using Atogepant tablets to prevent migraines in teens aged 12 to 17

  This study is testing if Atogepant tablets can help prevent migraines in teenagers aged 12 to 17.

  Recruiting at 61 sites Phase 3 AbbVie · Huntsville, Alabama and 65 other locations · NCT06810505

• Evaluating a new treatment for advanced non-squamous lung cancer

  This study is testing a new combination of medications for adults with advanced lung cancer who haven't had treatment before, to see if it is safe and effective.

  Recruiting at 123 sites Phase 1/2 AbbVie · Phoenix, Arizona and 126 other locations · NCT06772623

• Assessing the effects of risankizumab on ulcerative colitis in adults

  This study is testing how well risankizumab works for adults with moderate to severe ulcerative colitis by looking at their progress over a year while they receive the treatment from their doctors.

  Recruiting at 57 sites AbbVie · Heidelberg, Baden-Wurttemberg and 56 other locations · NCT06764706

• Assessing long-term use of Risankizumab for Psoriatic Arthritis

  This study is testing how well Risankizumab works over a long time for adults with psoriatic arthritis who haven't had enough relief from other treatments.

  Recruiting at 131 sites AbbVie · Quilmes, Buenos Aires and 131 other locations · NCT06764693

• Assessing a new injectable gel for improving mid-face volume

  This study is testing a new injectable gel to see if it can safely and effectively restore volume in the mid-face for adults who have lost fullness due to aging, comparing it to an existing treatment.

  Recruiting at 15 sites Phase 3 AbbVie · Birmingham, Alabama and 14 other locations · NCT06734351

• Comparing the effectiveness of Upadacitinib and TNF inhibitors for rheumatoid arthritis in Germany

  This study is testing whether Upadacitinib works better than traditional TNF inhibitors for adults with moderate to severe rheumatoid arthritis in Germany.

  Recruiting at 74 sites AbbVie · Freiburg im Breisgau, Baden-Wurttemberg and 74 other locations · NCT06712628

• Oral icalcaprant for adults with bipolar I or II: safety and symptom change

  This trial will test whether taking oral icalcaprant once daily for six weeks is safe and helps reduce depressive symptoms in adults with bipolar I or II disorder.

  Recruiting at 33 sites Phase 2 AbbVie · Huntsville, Alabama and 32 other locations · NCT06696755

• Mirvetuximab soravtansine for platinum-resistant high-grade ovarian, fallopian tube, and primary peritoneal cancer with high folate receptor-alpha

  This trial tests whether intravenous mirvetuximab soravtansine helps people with platinum-resistant high-grade ovarian, fallopian tube, or primary peritoneal cancer whose tumors have high folate receptor-alpha.

  Recruiting at 52 sites Phase 2 AbbVie · Sarasota, Florida and 51 other locations · NCT06682988

• Assessing the safety and effectiveness of Atogepant for migraine prevention in Korean adults

  This study is testing how well and safely Atogepant works for preventing migraines in Korean adults who have chronic or episodic migraines.

  Recruiting at 36 sites AbbVie · Busan, Busan Gwang Yeogsi and 35 other locations · NCT06603558

• Assessing Upadacitinib Treatment in Adults with Inflammatory Bowel Disease in Belgium

  This study is testing how well the medication upadacitinib works and how safe it is for adults with moderate to severe ulcerative colitis and Crohn's disease in Belgium over three years.

  Recruiting at 11 sites AbbVie · Bonheiden, Antwerpen and 10 other locations · NCT06581042

• Evaluating a new method for breast reconstruction after mastectomy

  This study is testing a new method for breast reconstruction using the ARTIA Reconstructive Tissue Matrix to see if it works better than the standard care for women who have had a mastectomy.

  Recruiting at 15 sites Phase 3 AbbVie · Los Angeles, California and 22 other locations · NCT06575192

• Assessing the safety of telisotuzumab vedotin in adults with non-small cell lung cancer

  This study is testing a new drug called telisotuzumab vedotin to see if it is safe for adults with non-small cell lung cancer that has already been treated.

  Recruiting at 80 sites Phase 2 AbbVie · Chandler, Arizona and 82 other locations · NCT06568939

• Targeted therapies for treating moderate to severe Crohn's disease in adults

  This study is testing new targeted treatments for adults with moderate to severe Crohn's disease who haven't found relief with current options to see if they can improve symptoms and reduce inflammation.

  Recruiting at 230 sites Phase 2 AbbVie · Dothan, Alabama and 254 other locations · NCT06548542

• Assessing molecular changes in adults with moderate to severe skin conditions receiving Lutikizumab

  This study is testing a new drug called Lutikizumab to see if it can help adults with moderate to severe skin conditions like hidradenitis suppurativa and atopic dermatitis feel better.

  Recruiting at 2 sites Phase 2 AbbVie · Sacramento, California and 1 other locations · NCT06524635

• Evaluating the risk of tumor lysis syndrome in adults with chronic lymphocytic leukemia receiving venetoclax with obinutuzumab or acalabrutinib

  This study is testing if the combination of venetoclax with either obinutuzumab or acalabrutinib is safe for adults with untreated chronic lymphocytic leukemia.

  Recruiting at 69 sites Phase 3 AbbVie · Tucson, Arizona and 69 other locations · NCT06428019

• Assessing the effects of Etentamig on AL Amyloidosis in adults

  This study is testing a new drug called Etentamig to see if it can help adults with AL amyloidosis feel better and manage their symptoms.

  Recruiting at 23 sites Phase 1/2 AbbVie · Miami, Florida and 22 other locations · NCT06158854

• Assessing the safety and effectiveness of risankizumab and adalimumab in children with juvenile psoriatic arthritis

  This study is testing a new medication called risankizumab to see if it works better and is safer than the standard treatment adalimumab for children with juvenile psoriatic arthritis.

  Recruiting at 34 sites Phase 3 AbbVie · Little Rock, Arkansas and 33 other locations · NCT06100744

• Assessing the effects of ABBV-400 on advanced solid tumors

  This study is testing a new drug called ABBV-400 to see if it can help adults with advanced solid tumors like liver, pancreatic, and triple negative breast cancer feel better and manage their disease.

  Recruiting at 47 sites Phase 1 AbbVie · Duarte, California and 53 other locations · NCT06084481

• Assessing the effectiveness of upadacitinib for treating Crohn's disease in Japan

  This study is testing if upadacitinib can help teenagers and adults in Japan with moderate to severe Crohn's disease feel better and stay safe while using the medication.

  Recruiting at 104 sites AbbVie · Anjo-shi, Aichi-ken and 103 other locations · NCT06023030

• Upadacitinib tablets for severe alopecia areata in adolescents and adults

  This trial will try upadacitinib tablets to see if they are safe and help regrow hair in adolescents and adults with severe alopecia areata.

  Recruiting at 46 sites Phase 3 AbbVie · Birmingham, Alabama and 271 other locations · NCT06012240

• Assessing the effects of risankizumab in children with Crohn's Disease

  This study is testing a new medication called risankizumab to see if it helps children with Crohn's Disease who haven't gotten better with other treatments.

  Recruiting at 79 sites Phase 3 AbbVie · Phoenix, Arizona and 84 other locations · NCT05995353

• Assessing Atogepant for Treating Pediatric Migraines

  This study is testing if Atogepant tablets can help children aged 6 to 17 with migraines feel better by reducing how often and how badly their headaches happen.

  Recruiting at 66 sites Phase 3 AbbVie · Huntsville, Alabama and 97 other locations · NCT05711394

• Assessing the safety of ABBV-383 in adults with relapsed or refractory multiple myeloma

  This study is testing a new drug called ABBV-383 to see if it's safe for adults with relapsed or refractory multiple myeloma and how it affects their symptoms.

  Recruiting at 39 sites Phase 1 AbbVie · Phoenix, Arizona and 43 other locations · NCT05650632

• Evaluating Upadacitinib and Tocilizumab for Treating Systemic Juvenile Idiopathic Arthritis in Children

  This study is testing whether a new drug called upadacitinib is safe and effective for children and teens with systemic juvenile idiopathic arthritis compared to an existing treatment called tocilizumab.

  Recruiting at 40 sites Phase 3 AbbVie · Phoenix, Arizona and 44 other locations · NCT05609630

• Assessing the effectiveness of venetoclax and azacitidine for treating acute myeloid leukemia in adults

  This study is testing if a combination of venetoclax tablets and azacitidine injections can help adults with newly diagnosed acute myeloid leukemia feel better and improve their treatment outcomes.

  Recruiting at 2 sites AbbVie · Medellín, Antioquia and 7 other locations · NCT05587049

• Assessing the effects of migraine treatments during pregnancy

  This study is testing how safe and effective migraine treatments Ubrelvy and Qulipta are for pregnant women and their babies.

  Recruiting at 2 sites AbbVie · Durham, North Carolina and 1 other locations · NCT05158894

• Evaluating Ubrogepant for treating migraines in children and adolescents

  This study is testing if ubrogepant can safely help kids and teens aged 6-17 with migraines and to find out the best dose for them.

  Recruiting at 91 sites Phase 3 AbbVie · Huntsville, Alabama and 128 other locations · NCT05125302

• Assessing the safety and effects of Azirkitug in cancer patients

  This study is testing a new cancer drug called Azirkitug to see how safe it is and how well it works for adults with certain types of lung and head and neck cancers.

  Recruiting at 47 sites Phase 1 AbbVie · Duarte, California and 47 other locations · NCT05005403

• Comparing Telisotuzumab Vedotin and Docetaxel for Non-Small Cell Lung Cancer

  This study is testing whether a new drug called telisotuzumab vedotin is better than the standard treatment docetaxel for adults with a specific type of lung cancer that has already been treated.

  Recruiting at 263 sites Phase 3 AbbVie · Birmingham, Alabama and 316 other locations · NCT04928846

• Assessing the effects of venetoclax and obinutuzumab in adults with recurring chronic lymphocytic leukemia

  This study is testing if a combination of two medications, venetoclax and obinutuzumab, can help adults with recurring chronic lymphocytic leukemia feel better after their previous treatments.

  Recruiting at 50 sites Phase 2 AbbVie · La Jolla, California and 57 other locations · NCT04895436

• Evaluating pregnancy outcomes in women exposed to risankizumab

  This study looks at how pregnancy outcomes differ for women with conditions like psoriasis and Crohn's disease who have used risankizumab compared to those who haven't.

  Recruiting AbbVie · Morrisville, North Carolina and 1 other locations · NCT04846959

• Assessing Cariprazine for Treating Depression in Teens with Bipolar I Disorder

  This study is testing if a medication called cariprazine can help teenagers with bipolar I disorder feel better during depressive episodes.

  Recruiting at 32 sites Phase 3 AbbVie · Bentonville, Arkansas and 80 other locations · NCT04777357

• Venetoclax for chronic lymphocytic leukemia in real-world care

  This study will see how well venetoclax works and how patients do when it is used alone or with other common CLL drugs in routine clinical care.

  Recruiting at 5 sites AbbVie · Sankt Pölten, Lower Austria and 73 other locations · NCT03342144

Quick answers

How many clinical trials run by AbbVie are recruiting right now?

111, as of November 12, 2026. 4 of them were first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 49 countries. The most sites are in United States (84 trials), Japan (41 trials), Spain (36 trials), Israel (30 trials), Canada (29 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 26, Phase 3: 22, Phase 1: 22, Phase 1/2: 6. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →